Paul Le Floch talks BCI, Coma and Start Up Dynamics

How can softer materials make implantable brain-computer interfaces safer, more stable and clinically useful? In this episode of The Business of Neurotech, Adam Fraser is joined by Dr Paul Le Floch, co-founder and CEO of Axoft, to explore how his materials science background led to Fleuron, a soft neural interface platform designed to reach deep brain regions while maintaining high-density recordings. Dr Le Floch explains why Axoft is initially focusing on disorders of consciousness, how the company is taking a stepwise path through FDA clearance and what its early clinical work revealed about turning novel biomaterials into medical devices. He also discusses the realities of raising a $55 million Series A, competing in a fast-moving BCI market, financing research through materials sales and learning to pitch a long-term vision as a scientist-founder. Tune in to learn what it takes to build an invasive BCI company focused on better materials, unmet clinical needs and patient impact. Key Points From This Episode: 01:29 Dr Le Floch’s path from materials science at Harvard to founding Axoft. 03:21 Discover why the brain’s electrical complexity drew him into neuroscience. 04:57 Unpack how Fleuron’s softness aims to improve compatibility with brain tissue. 06:44 Explore why stable neural data links efficacy with reduced tissue disruption. 08:58 Compare invasiveness with signal quality and where Axoft sits on that continuum. 12:19 Find out why disorders of consciousness became Axoft’s first clinical focus. 16:26 Follow the roadmap from diagnosis and prognosis towards decoding communication. 18:12 Understand Axoft’s stepwise regulatory strategy for a temporary inpatient device. 20:15 He shares his experience working with the FDA in an emerging BCI category. 21:34 Uncover the clinical evidence and commercial plan behind Axoft’s Series A. 23:25 The clearance, manufacturing and clinical milestones needed for Series B funding. 25:14 Gain insight into why BCI’s difficult venture capital environment is still worth the risk. 28:47 Unpack Axoft’s strategy in a field of well-funded but complementary competitors. 30:12 Hear how materials sales fund research while providing partnership opportunities. 33:35 Why targeted stimulation that bridges devices and drugs is capturing his attention. 35:11 Learn how scientist-founders can move from research to vision-led application. 37:18 Final takeaways and how to learn more about Axoft and Dr Le Floch’s work. Links Mentioned in Today’s Episode: Dr Paul Le Floch on LinkedIn -   / plefloch   Axoft - https://axoft.us/ Axoft on LinkedIn -   / axoftus   Episode 5: Naveen Rao Talks Neurotech Market Dynamics - https://www.businessofneurotech.com/p... Episode 8: Nicolas Vachicouras Talks BCI Market Dynamics and Start Up Life - https://www.businessofneurotech.com/p... Episode 12: Matt Angle Talks Paradromics and BCI Market Dynamics - https://www.businessofneurotech.com/p... Mass General Brigham - https://www.massgeneralbrigham.org/ FDA Breakthrough Devices Program - https://www.fda.gov/medical-devices/h... iBCI Collaborative Community (iBCI-CC) - https://www.ibci-cc.org/ Adam Fraser on LinkedIn -   / adam-fraser-23202133   Omniscient Neurotechnology - https://www.o8t.com/ The Business of Neurotech Podcast - https://www.businessofneurotech.com/